Amicus therapeutics, inc. (FOLD)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Mar'12
Operating activities
Net loss

-88,948

-89,729

-61,809

-84,551

-120,299

-78,081

-159,163

-61,835

-49,916

-69,208

-111,665

-48,137

-54,992

-58,647

-46,654

-51,050

-43,691

-42,896

-37,801

-27,133

-24,288

-21,220

-17,149

-14,614

-15,943

-13,137

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred financing

231

256

186

455

1,649

3,108

2,595

2,672

2,601

2,524

2,464

2,312

2,403

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

1,764

1,514

1,116

1,154

991

1,201

1,073

973

969

1,107

850

813

823

906

896

767

673

577

395

353

508

364

375

396

412

420

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

563

451

356

0

53

83

101

61

56

59

-

Amortization of non-cash compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation

12,596

12,908

8,843

9,935

12,744

8,387

7,054

6,341

7,478

6,034

5,500

5,537

6,030

4,417

4,339

4,465

4,283

3,043

2,738

2,231

1,960

1,610

1,650

1,488

1,260

1,388

Loss on exchange of convertible debt

0

0

24

-4,524

-36,100

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

0

11

8

50

-29

8

26

10

11

15

-81

-8

-

Change in fair value of derivatives

-

-

-

-

-

0

0

-7,600

4,861

0

0

102

163

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash changes in the fair value of contingent consideration payable

931

645

789

480

1,383

600

1,300

300

1,100

4,300

-244,250

1,050

4,578

-2,468

-4,110

10,186

3,152

1,977

1,300

100

1,000

-

-

-305

505

-

Foreign currency remeasurement loss

-10,662

2,411

-2,135

-205

-325

-2,442

1,332

-5,064

2,957

688

1,929

2,399

604

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash deferred taxes

-

-

-

-

-

-

-

-

-

331,890

-164,683

49

49

-

-

-

-

-

-

-

-

-

-

-

-

-

(Gain) loss on disposal of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-27

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,376

Stock-based compensation - non-employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based license payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Beneficial conversion feature related to bridge financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Accounts receivable

8,358

-1,530

5,815

5,828

1,001

8,112

-861

4,996

1,047

3,437

2,062

1,714

512

-

-

-

-

-

-

-

-

-293

-183

-18

-589

-742

Inventories

251

3,098

108

2,253

-345

2,156

-1,400

196

3,253

-2,489

3,035

108

243

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-4,016

-34

-202

6,582

-3,059

145

1,951

6,291

-10,875

11,971

1,255

-3,743

5,846

-2,409

1,938

771

94

-976

1,309

-223

-418

1,140

812

-352

-3,893

-3,114

Other non-current assets

-

-

-

-

-

-

-

-

-

-

-859

57

458

310

111

172

377

126

58

85

397

-

-

-

-

-267

Accounts payable and accrued expenses

-35,251

38,028

-3,739

21,311

-8,858

13,431

15,485

-1,454

-10,347

-474

17,334

-3,026

-1,271

10,051

5,324

1,519

-9,763

1,349

13,659

1,010

-551

4,956

1,368

832

-987

-1,259

Other non-current assets and liabilities

-5,334

-12,081

2,783

2,688

-3,507

-161

-84

-173

-163

-646

141

133

363

141

149

155

380

126

51

-366

282

-

-

-

-

-

Deferred reimbursements

0

-4,000

0

0

-1,500

-1,250

0

-5,000

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,977

Net cash used in operating activities

-107,942

-57,832

-55,553

-58,485

-78,546

-60,677

-132,762

-56,995

-49,521

-73,034

-48,904

-41,914

-49,843

-31,598

-40,878

-32,735

-44,936

-35,511

-21,017

-22,636

-20,975

-14,508

-15,122

-11,819

-10,220

-8,039

Investing activities
Sale and redemption of marketable securities

106,140

109,805

127,817

126,238

135,187

75,367

177,896

89,013

121,226

92,772

93,072

68,466

69,443

55,879

44,212

68,126

53,157

156,711

70,255

22,424

40,739

7,955

16,845

19,649

11,465

14,300

Purchases of marketable securities

12,088

71,917

120,647

139,140

52,178

137,431

60,729

77,224

303,010

40,110

265,864

23,371

161,123

20,103

72,915

76,193

50,721

68,734

190,447

12,093

18,321

87,643

46,260

11,622

17,227

67,906

Capital expenditures

806

10,925

3,977

2,166

2,944

1,737

2,690

1,062

819

1,128

1,119

1,547

732

431

912

1,730

2,878

2,571

817

676

753

46

60

92

40

3,082

Net cash provided by investing activities

93,246

26,963

3,193

-15,068

80,065

-63,801

114,477

10,727

-182,603

51,534

-173,911

43,548

-92,412

35,345

-29,615

-9,797

-442

85,406

-262,069

9,655

21,665

-79,734

-29,475

7,935

-5,802

-56,688

Financing activities
Proceeds from the issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from Issuance of Common Stock

-

-

-

-

-

0

0

0

294,584

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

62,063

Payment of finance leases

21

243

79

23

75

116

76

71

71

96

70

71

71

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of secured loan agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

100

99

100

313

Purchase of vested restricted stock units

7,543

234

446

617

1,938

151

654

115

1,912

529

64

742

261

272

353

0

657

-

-

-

-

-

-

-

-

-

Proceeds from termination of capped call confirmations

0

-39,750

-25

5,300

14,600

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

6,077

3,668

1,048

2,807

3,953

652

912

3,602

3,978

7,460

7,287

1,289

265

1,580

809

492

155

513

3,741

2,869

4,063

1,576

2,072

10

15

837

Payment of deferred financing fees

-

-

-

-

-

-

-

-

-

-

0

0

28

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds of exercise of warrants

0

0

0

0

812

0

0

3,617

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital expenditures funded by capital lease

-

-

-

-

-

-

-

-61

142

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent consideration

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from exercise of warrants (common and preferred)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from capital asset financing arrangement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from loan agreements, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

995

Net cash (used in) provided by financing activities

-1,487

3,191

523

196,404

17,384

359

146,804

7,033

296,579

6,864

250,189

-9,524

-95

150,319

39,635

83,263

-502

151

53,502

233,177

4,063

98,645

22,364

18,255

-85

63,582

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

-4,265

4,320

-1,650

1,409

-2,350

2,664

-130

-1,876

860

296

416

534

80

232

317

-585

-95

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period

-20,448

-23,358

-53,487

124,260

16,553

-121,455

128,389

-41,111

65,315

-14,340

27,790

-7,356

-142,270

154,298

-30,541

40,146

-45,975

50,046

-229,584

220,196

4,753

4,403

-22,233

14,371

-16,107

-1,145

Supplemental disclosures of cash flow information
Tenant improvements paid through lease incentives

254

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

3,693

3,821

3,843

4,456

4,846

3,713

13

3,762

12

3,762

12

3,638

12

-

-

-

-

0

0

396

209

322

327

329

208

20

Contingent consideration paid in shares

0

-

-

-

9,316

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital expenditures unpaid at the end of period

589

-937

1,965

837

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash activities
Conversion of notes payable to Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Beneficial conversion feature related to the issuance of Series C redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0